## **Trustees’ Annual Report for the period** 

## **From  1[st] January 2025    To 31[st] December 2025** 

## **Charity name:  Salivary Gland Cancer UK** 

## **Charity registration number:  1182762** 

## **Objectives and Activities** 

||SORP reference||
|---|---|---|
|Summary of the purposes of<br>the charity as set out in its<br>governing document|Para 1.17|Help those affected by rare salivary gland<br>cancers.<br>Advocate for these patients and carers by<br>providing peer support and information<br>about their disease, care and treatment.<br>Promote and assist research into all aspects<br>of salivary gland cancers, including causes,<br>diagnosis, treatments and cures.<br>To educate the public and healthcare<br>communities in all things related to salivary<br>gland cancers, including raising awareness<br>of symptoms.|
|Summary of the main<br>activities in relation to those<br>purposes for the public<br>benefit, in particular, the<br>activities, projects or<br>services identified in the<br>accounts.|Para 1.17 and<br>1.19|•<br>Supporting the community via in person<br>and virtual meetings for patients, carers<br>and clinicians.<br>•<br>Providing information and increasing<br>awareness via leaflets, meetings, the<br>website, social media and fundraising<br>events.<br>•<br>Raising awareness of these cancers and<br>their<br>unmet<br>need<br>via<br>speaking,<br>submitting<br>materials<br>and<br>attending<br>meetings and conferences.<br>•<br>Expansion of the network to support all<br>salivary gland cancer types.<br>•<br>Expansion of the charity’s outputs to<br>provide more research and disease<br>specific information.|
|Statement confirming<br>whether the trustees have<br>had regard to the guidance<br>issued by the Charity<br>Commission on public<br>benefit|Para 1.18|The trustees have kept in mind the charity<br>Constitution and the guidance from the<br>Charities Commission in all of its’ activities.<br>The governance documents of the Charity<br>are regularly reviewed at Trustee meetings.|



1 



The charity’s “8 aims” are regularly published via our social media outlets and are the foundation for all activities and decisions within the charity. The trustees ensure the prioritisation of activities is aligned with these aims. 

**Additional information (optional)** You may choose to include further statements where relevant about: 

||SORP reference||
|---|---|---|
|Policy on grant making|Para 1.38|We invest directly in research<br>infrastructure. Our first grant call funded<br>projects mapping the pathway to diagnosis<br>and developing guidance to support earlier<br>detection.<br>We have supported the rollout of a UK-wide<br>surgical registry, which collects clinical and<br>patient-reported outcomes data to improve<br>understanding of treatment outcomes and<br>disease progression.<br>We also rolled out our very first travel grant<br>so our community can apply for financial<br>support to travel to a relevant conference or<br>workshop that is aligned with our strategy<br>as a charity. This is available to those who<br>do not otherwise receive funding to attend<br>such events e.g. medical undergraduates,<br>allied healthcare professionals and patient<br>advocates.|
|Policy on social investment<br>including program related<br>investment|Para 1.38||
|Contribution made by<br>volunteers|Para 1.38|We are hugely grateful for the continued<br>support and contribution we received from<br>our volunteers assisting us in specific<br>projects and outputs, sharing their stories<br>on social media channels, and ‘on the day’<br>physical support at both our own events<br>and conferences we attend.|
|Other|||



2 



## **Achievements and Performance** 

||SORP reference||
|---|---|---|
|Summary of the main<br>achievements of the charity,<br>identifying the difference the<br>charity’s work has made to<br>the circumstances of its<br>beneficiaries and any wider<br>benefits to society as a<br>whole.|Para 1.20|**_Launch of annual Salivary Gland Cancer_**<br>**_Day – 4th October 2025_**<br>SGC Day was launched on 4 October 2025<br>at Manchester Art Gallery - the first<br>awareness day dedicated to these cancers<br>in the UK.<br>The initiative was created to address a<br>major barrier to progress: the lack of public<br>and professional awareness surrounding<br>salivary gland cancers. Through<br>coordinated social media campaigns,<br>patient storytelling and community<br>engagement, the day brought<br>unprecedented visibility to SGCUK and<br>these rare diseases.<br>Patients, clinicians and supporters across<br>the UK and internationally participated.<br>Social media posts were created in 25<br>languages ensuring as wide a reach as<br>possible.  The success of the inaugural<br>annual awareness day has established a<br>powerful platform for future national<br>awareness campaigns.<br>**_Bringing together those living with_**<br>**_salivary gland cancers_**<br>We continued to host bi-annual hybrid (in<br>person/virtual)<br>meetings<br>during<br>2025,<br>supporting attendees with travel bursaries<br>for patients and their carers where needed.<br>The hybrid structure of our events has<br>facilitated strong attendance from our<br>community<br>across<br>the<br>country<br>and<br>internationally. In May 2025 we hosted a<br>gathering in Sheffield and October 2025’s<br>event was in Manchester.<br>We<br>provided<br>regular<br>communications,<br>newsletters and updates to the network. We<br>continued to produce our video series,<br>releasing recordings of the presentations at<br>our hybrid meetings to ensure we reach as<br>many<br>people<br>as<br>possible.<br>We<br>also<br>continued to add patient stories on social<br>media and on our website.<br>We also hosted a number of ‘stop by’<br>sessions online where the community could|



3 



|drop in for a chat with members of our team|
|---|
|about anything they wanted to discuss.|
|**_Raising awareness amongst the general_**|
|**_public and the clinical community_**|
|We continue to work to increase our visibility|
|among the clinical and patient network by|
|attending<br>and<br>presenting<br>at<br>various|
|conferences and events.|
|In March we attended ESMO Rare Cancers|
|Congress where Dr Metcalf delivered a|
|presentation on behalf of the UK Salivary|
|Gland Cancer Research Working Group|
|(UKSGCRWG), titled “Advancing Salivary|
|Gland Cancer Research: A Multidisciplinary|
|Approach to Addressing the Unmet Clinical|
|Need.”|
|In June, we chaired a panel discussion at|
|the inaugural National Patient Data Day,|
|hosted by use MY data, delving into the|
|critical question: 'Can we create a UK-wide|
|data environment fit for international rare|
|disease research?'|
|In July we attended IAOO2025, where we|
|had a stall and our CEO Dr Emma Kinloch|
|delivered a keynote speech on patient|
|voices in research. IAOO 2025 is the 10th|
|World<br>Congress<br>of<br>the<br>International|
|Academy<br>of<br>Oral<br>Oncology,<br>bringing|
|together over 1,000 delegates from various|
|disciplines involved in oral cancer care.|
|We attended the Swallows Head and Neck|
|Conference in November to ensure SGC|
|patient<br>needs<br>are<br>represented<br>in|
|discussions on the latest surgical and|
|radiotherapy treatments.|
|We<br>also<br>joined<br>the<br>Cancer<br>Drug|
|Development Forum (CDDF) workshop in|
|November, titled "Enabling Smarter Clinical|
|Trials to Optimise Patient Care."|
|Our Patient and Public Involvement (PPI)|
|work has continued to grow and develop in|
|2025. We are regularly called upon to input|
|into the design of research studies, provide|
|feedback on trial protocols, help researchers|
|develop lay summaries of their work and|
|bring the perspective of those with lived|
|experiences to discussions.|



4 



|Many fundraising events, both large and|
|---|
|small, have taken place during the year,|
|notably our supporters’ participation in the|
|London and Loch Ness Marathons and The|
|Big Half in London.|
|**_Bringing together the patient, clinical_**|
|**_and research communities to help drive_**|
|**_forward research and improvements in_**|
|**_treatments_**|
|Our Research Working Group has been|
|very active during 2025. Consisting of|
|clinicians,<br>researchers<br>and<br>patient|
|advocates from all around the UK and|
|beyond.|
|The group meets twice a year in full with 4|
|separate workstreams meeting throughout|
|the year to focus on their individual topics in|
|line with the charity’s aims.|
|Our involvement on the PRONTO trial|
|management committee continued as it|
|opened for recruitment at The Christie and|
|UCLH, representing a significant step|
|forward in optimising care for Salivary Gland|
|Cancer. The primary focus of this study is on|
|patient quality of life.|



**Additional information (optional)** You may choose to include further statements where relevant about: 

Achievements against Para 1.41 objectives set Performance of fundraising Para 1.41 activities against objectives set Investment performance Para 1.41 against objectives Other 

5 



## **Financial Review** 

|**Financial Review**|||
|---|---|---|
|Review of the charity’s<br>financial position at the end<br>of the period|Para 1.21|As at 31stDecember 2025 the charity held a<br>cash balance of £50,077, (prior year<br>£68,381). The charity had an in-year deficit of<br>£18,304 (prior year deficit £36,451).<br>The charity received income of £39,609 (prior<br>year £37,336) from donations raised through<br>fund raising initiatives and personal legacies.<br>The charity’s accounts for the year have been<br>independently reviewed with no issues<br>raised.<br>Despite an in-year deficit, the charity’s<br>financial position remains robust. There are<br>substantial fundraising activities planned for<br>2026 and we are predicting an in-year<br>surplus.|
|Statement explaining the<br>policy for holding reserves<br>stating why they are held|Para 1.22|The cash balance is held in order to support<br>the overall objectives of the charity. Cash is<br>used to cover operating expenses, develop<br>the charity’s presence through marketing and<br>fund specific patient/clinician events. Cash<br>held is also the source funds for the grants we<br>have issued and for any other grant making<br>opportunities that may arise.|
|Amount of reserves held|Para 1.22|£50,077 in cash.|
|Reasons for holding zero<br>reserves|Para 1.22|Not applicable|
|Details of fund materially in<br>deficit|Para 1.24|Not applicable|
|Explanation of any<br>uncertainties about the<br>charity continuing as a going<br>concern|Para 1.23|There are no uncertainties around the<br>charity’s ability to continue as a going<br>concern. The Board, together with the CEO,<br>carefully consider the on-going running costs<br>of the charity when assessing the funds<br>available for grants and other events.|



|**Additional information (optional)**<br>You may choose to include further statements|**Additional information (optional)**<br>You may choose to include further statements|where relevant about:|
|---|---|---|
|The charity’s principal<br>sources of funds (including<br>any fundraising)|Para 1.47||
|Investment policy and<br>objectives including any<br>social investment policy<br>adopted|Para 1.46||
|A description of the principal<br>risks facing the charity|Para 1.46|The Board maintains a Risk Register for<br>the charity. This document highlights<br>governance, operational, financial,<br>compliance and external risks and the<br>mitigants in place. The Board reviews the<br>Risk Register periodically.|
|Other|||



6 



## **Structure, Governance and Management** 

|Description of charity’s<br>trusts:|||
|---|---|---|
|Type of governing document<br>(trust deed, royal charter)|<br>Para 1.25|The charity is governed by its Constitution.|
|How is the charity<br>constituted?<br>(e.g unincorporated<br>association, CIO)|Para 1.25|The charity is a Charitable Incorporated<br>Organisation.|
|Trustee selection methods<br>including details of any<br>constitutional provisions e.g.<br>election to post or name of<br>any person or body entitled<br>to appoint one or more<br>trustees|Para 1.25|Trustees must be appointed for a term by a<br>resolution passed at a properly convened<br>meeting of the charity trustees.<br>When selecting trustees, the charity trustees<br>have regard to the skills, knowledge and<br>experience<br>needed<br>for<br>the<br>effective<br>administration of the CIO. The Board<br>periodically reviews a detailed skills matrix<br>to identify any gaps and regularly discusses<br>the structure and composition of the Board<br>to ensure its ongoing effectiveness as a<br>governing body.|



**Additional information (optional)** You may choose to include further statements where relevant about: 

|Policies and procedures<br>adopted for the induction<br>and training of trustees|Para 1.51|All new trustees undertake an induction<br>process which includes receiving an<br>induction pack containing relevant policies,<br>procedures and key organisational<br>information, together with an individual<br>meeting with the CEO. Prospective trustees<br>are also invited to attend Board meetings<br>as observers prior to their formal<br>appointment, enabling them to gain an<br>understanding of the charity’s governance,<br>operations and responsibilities of trustees.<br>Ongoing training and development needs<br>are identified as appropriate throughout<br>their tenure.|
|---|---|---|
|The charity’s organisational<br>structure and any wider<br>network with which the<br>charity works|Para 1.51||
|Relationship with any<br>related parties|Para 1.51||
|Other|||



7 



## **Reference and Administrative details** 

|Charity name|Salivary Gland Cancer UK|
|---|---|
|Other name the charity uses||
|Registered charity number|1182762|
|Charity’s principal address|International House<br>36-38 Cornhill<br>City of London<br>London<br>EC3V 3NG|
|||



8 



## **Names of the charity trustees who manage the charity** 

|1<br>2<br>3<br>4<br>5<br>6|**Trustee name**|**Office (if any)**|**Dates acted if not for whole**<br>**year **|**Name of person (or body) entitled**<br>**to appoint trustee (ifany)**|
|---|---|---|---|---|
||Dr Robert Metcalf|Trustee||The Board|
||Shane Lisa Draper|Trustee and Chief<br>Financial Officer||The Board|
||Olorunkemi Fausat<br>Akanke Olaiya|Treasurer|**Non-Board role|The Board|
||Jacqueline<br>O’Connor|Chair of Board|Start date – December<br>2025|The Board|
||Sally Crowe|Trustee|Start date – December<br>2025|The Board|
||Barry Thomas|Trustee|Start date – December<br>2025|The Board|
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||
||||||



## – Corporate trustees names of the directors at the date the report was approved 

**Director name** 

Name of trustees holding title to property belonging to the charity 

**Trustee name Dates acted if not for whole year** 

9 



## **Funds held as custodian trustees on behalf of others** 

Description of the assets Not applicable held in this capacity Name and objects of the Not applicable charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for Not applicable safe custody and segregation of such assets from the charity’s own assets 

## **Additional information (optional)** 

## **Names and addresses of advisers (Optional information)** 

|**Type of**|**Name**|**Address**|
|---|---|---|
|**adviser**|||



**Name of chief executive or names of senior staff members (Optional information)** 

Dr Emma Kinloch - CEO 

## **Exemptions from disclosure** 

Reason for non-disclosure of key personnel details 

## **Other optional information** 

10 



## **Declarations** 

**The trustees declare that they have approved the trustees’ report above.** 

**Signed on behalf of the charity’s trustees** 

|**Signature(s)**<br>**Full name(s)**<br>**Position (eg Secretary,**<br>**Chair, etc) **<br>**Date**|||
|---|---|---|
||Jacqueline O’Connor|Shane Lisa Draper|
||<br> Chair of the Board of Trustees|Chief Financial Officer|
||19.10.26<br>19.10.26||
||19.10.26||



11 



||**Salivary Gland Cancer UK**<br> <br>|**Salivary Gland Cancer UK**<br> <br>|**Salivary Gland Cancer UK**<br> <br>|**No (if any)**<br>**1182762**|**CC16a**|
|---|---|---|---|---|---|
||**Receipts and payments accounts**|||||
||**For the period**<br>**from**|Period start date<br>**1st January 2025**|**To**|Period end date<br>**31st December 2025**||
|||||||
|**Section A Receipts and payments**||||||
|**A1 Receipts**|**Unrestricted**<br>**funds**<br>**to the nearest**<br>**£**<br>**35,740**<br>**2,197**<br>**-**<br>**384**<br>**325**<br>**964**<br>**-**<br>**-**<br>**-**<br>**-**<br>**39,609**|**Restricted funds**<br>**to the nearest £**|**Endowment**<br>**funds**<br>**to the nearest £**|**Total funds**<br>**to the nearest £**|**Last year**<br>**to the nearest £**|
|Donations via Just Giving, Easy Fundraising,<br>Paypal and otherplatforms||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**|**35,740**|**24,029**|
|Donations received from<br>organisations/individuals|||**-**|**2,197**|**11,183**|
|Grants from organisations/collaboration<br>agreements|||**-**|**-**|**840**|
|Shop income|||**-**|**384**|**-**|
|Other income|||**-**|**325**|**-**|
|Bank interest|||**-**|**964**|**1,285**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
|**_Sub total_**_(Gross income for AR)_||**-**|**-**|**39,609**|**37,336**|



**A2 Asset and investment sales, (see table).** 

|**_Sub total_**_(Gross income for AR)_|**_Sub total_**_(Gross income for AR)_|**_Sub total_**_(Gross income for AR)_|**_Sub total_**_(Gross income for AR)_|**_Sub total_**_(Gross income for AR)_|**_Sub total_**_(Gross income for AR)_|
|---|---|---|---|---|---|
|**A2 Asset and investment sales,**<br>**(see table). **||||||
||**-**<br>**-**|**-**<br>**-**|**-**|**-**||
||||**-**|**-**|**-**|
|**_Sub total_**|<br>**-**|**-**|**-**|**-**|**-**|
|**_Total receipts_**<br>**A3 Payments**|**37,807**<br>**17,112**<br>**124**<br>**665**<br>**1,270**<br>**936**<br>**-**<br>**-**<br>**-**<br> <br>**57,913**|||||
|||**-**|**-**|**39,609**|**37,336**|
|||||||
|Charity admin expenses and running costs||**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**|**-**|**37,807**|**33,073**|
|In person meeting expenses e.g. room hire|||**-**|**17,112**|**17,379**|
|Bursaries for attendees|||**-**|**124**|**508**|
|Memberships and collaborative expenses|||**-**|**665**|**316**|
|Entry into events for members fundraising|||**-**|**1,270**|**1,510**|
|Grants|||**-**|**936**|**21,000**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
||||**-**|**-**|**-**|
|**_Sub total_**||**-**|**-**|**57,913**|**73,787**|



**A4 Asset and investment purchases, (see table)** 

|**A4 Asset and investment**<br>**purchases, (see table)**|**A4 Asset and investment**<br>**purchases, (see table)**|**A4 Asset and investment**<br>**purchases, (see table)**|**A4 Asset and investment**<br>**purchases, (see table)**|**A4 Asset and investment**<br>**purchases, (see table)**|**A4 Asset and investment**<br>**purchases, (see table)**|
|---|---|---|---|---|---|
||**-**|**-**|**-**|**-**||
||**-**|**-**|**-**|**-**||
|**_Sub total_**|<br>**-**|**-**|**-**|**-**|**-**|
|**_Total payments_**<br>**_Net of receipts/(payments)_**<br>**A5 Transfers between funds**<br>**A6 Cash funds last year end**<br>**_Cash funds this year end_**||||||
|||**-**|**-**|**57,913**|**73,787**|
|||||||
||**(18,304)**|**-**|**-**|**-**<br>**18,304**|**-**<br>**36,451**|
||**-**|**-**|**-**|**-**|**-**|
||**68,381**<br>**50,077**|**-**|**-**|**68,381**|**104,832**|
|||**-**|**-**|**50,077**|**68,381**|
|||||||
|**Section B Statement of assets and liabilities at the end of the period**||||||
|**Categories**<br>**B1 Cash funds**|**Details**<br>Bank account balance (Lloyds)<br>Notice account (Lloyds)||**Unrestricted**<br>**funds**<br>**to nearest £**<br>**16,268**<br>**32,856**|**Restricted funds**<br>**to nearest £**|**Endowment**<br>**funds**<br>**to nearest £**<br>**-**<br>**-**|
|||||**-**<br>**-**||





|||**953**||**-**||**-**|
|---|---|---|---|---|---|---|
|||**50,077**||**-**||**-**|
|||OK||OK||OK|
|||**Unrestricted**<br>**funds**<br>**to nearest £**<br>**Fund to which asset**<br>**belongs **<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**||**Restricted funds**<br>**to nearest £**<br>**Cost (optional)**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**<br>**-**||**Endowment**<br>**funds**<br>**to nearest £**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**-**|
|||||||**Current value**<br>**(optional)**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||||**Current value**<br>**(optional)**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||**-**||**-**|
|||||||**When due (optional)**|
|||||**-**|||
|||||**-**|||
|||||**-**|||
|||||**-**|||
|||||**-**|||
||||||||
|||||||Date of approval|
|||||||19.10.26|
|||||||19.10.26|
||||||||



Shane Draper 



CHARITY COMMISSION
FOR ENGLAND AND WALES
Independent examiner's
report on the accounts
Report to the trusteesl
members of
Salivary Gland Cancer UK
On accounts for the year
ended
31" December 2025
Charfty no
(if any)
1182762
Set out on pages
I report lo the trustees on my examination of the accounts ofthe above
charity ('the Trust") for the year ended 31st December 2025.
Responsibilities and As the charity trustees of the Trust, you are responsible for the preparation
basis of report of the accounts in accordance with the requirements of the Charits'es Act
20111.the ACV'I.
I report in respect of my examination of the Trust's accounls carried out
under section 145 of the 2011 Act and in carying oul my examination, I
have followed the applicable Directions given by the Charity Commission
under section 145(5)(bl of the Act.
I have Gompleted my examination. I confirm that no material matters have
come to my attention (other than that disclosed below ') in conneclion with
the examination which gives me cause to believe that in, any rnaterial
respect=
accounting records were not kept in accordan￿ with section 130 of
the Act or
the accounts do not accord with the accounting records
Independent
examinerfs statement
I have no concerns and have come across no other matters in connection
with the examination to which attention should be drawn in order to enable a
proper understanding of the accounts to be reached.
Please delete the words in the brackets if they do not apply.
Signed:
Date:
Name:
Mrs Karen Wicks
Relevant professTonal
qualification(sl or body
(rf any):
Accountant
Address:
On request
IER
October 2018

Only complete ifthe examiner needs lo highlight matters of Goncern (see CC32,
Independent examination of charity accoLsnts.' directions and guidance for
exarniners).
Give here brief details of
any items that the
examlner wishes to
disclose.
IER
October 2018